The Nippon India Pharma Fund - Growth has an AUM of 8638.23 crores & has delivered CAGR of 27.97% in the last 5 years. The fund has an exit load of 1.00% and an expense ratio of 1.81%. The minimum ...
Indian pharmaceutical companies have made major ... robust Standard Operating Procedures (SOPs), and ongoing employee training, Jain said. According to Jain, the senior leadership has prioritised ...
As every pharma company invests in digital technology ... we are overlooking the potential of such techniques for internal training. The way in which we communicate has changed radically over ...
“Indian pharma companies have undertaken substantial work in fostering a culture that prioritises quality. The senior leadership teams are committed to continually improving standards, supported by ...
This versatile immunotherapy holds the potential to make a significant impact for oncology patients in India,” the company said in a statement. Under the agreement, Mankind Pharma will have ...
India accounts for 20 per cent of the overall generic drug sales globally. As technological advancements like AI, machine learning and precision medicine revolutionise drug discovery ...
1. Current NAV: The Current Net Asset Value of the Nippon India Pharma Fund as of Dec 30, 2024 is Rs 524.96 for Growth option of its Regular plan. 2. Returns: Its trailing returns over different time ...
What does Nifty Pharma represent? Tracks the performance of pharmaceutical companies in India, comprising leading pharmaceutical stocks listed on the National Stock Exchange (NSE), reflecting trends ...